ID   KSR2_HUMAN              Reviewed;         950 AA.
AC   Q6VAB6; A0PJT2; Q3B828; Q8N775;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   29-MAY-2007, sequence version 2.
DT   12-OCT-2022, entry version 152.
DE   RecName: Full=Kinase suppressor of Ras 2;
DE            Short=hKSR2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:21441910};
GN   Name=KSR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 122-950 (ISOFORM 1), FUNCTION, INTERACTION
RP   WITH MAP2K; RAS; RAF; MAPK AND MAP3K8, AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=12975377; DOI=10.1074/jbc.m306002200;
RA   Channavajhala P.L., Wu L., Cuozzo J.W., Hall J.P., Liu W., Lin L.-L.,
RA   Zhang Y.;
RT   "Identification of a novel human kinase supporter of Ras (hKSR-2) that
RT   functions as a negative regulator of Cot (Tpl2) signaling.";
RL   J. Biol. Chem. 278:47089-47097(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 122-950 (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=16039990; DOI=10.1016/j.bbrc.2005.07.009;
RA   Channavajhala P.L., Rao V.R., Spaulding V., Lin L.-L., Zhang Y.G.;
RT   "hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in
RT   inflammation.";
RL   Biochem. Biophys. Res. Commun. 334:1214-1218(2005).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH BRAF; MAP2K1 AND MAP2K2.
RX   PubMed=29433126; DOI=10.1038/nature25478;
RA   Lavoie H., Sahmi M., Maisonneuve P., Marullo S.A., Thevakumaran N., Jin T.,
RA   Kurinov I., Sicheri F., Therrien M.;
RT   "MEK drives BRAF activation through allosteric control of KSR proteins.";
RL   Nature 554:549-553(2018).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (3.46 ANGSTROMS) OF 634-950 OF MUTANT ALA-786 IN
RP   COMPLEX WITH ATP AND MAP2K1, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, SUBUNIT, INTERACTION WITH BRAF AND MAP2K1, ACTIVE SITE, AND
RP   MUTAGENESIS OF ARG-718; ASP-786 AND ALA-879.
RX   PubMed=21441910; DOI=10.1038/nature09860;
RA   Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L.,
RA   Shokat K.M., Barford D.;
RT   "A Raf-induced allosteric transition of KSR stimulates phosphorylation of
RT   MEK.";
RL   Nature 472:366-369(2011).
RN   [8]
RP   VARIANT [LARGE SCALE ANALYSIS] SER-676.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Location-regulated scaffold connecting MEK to RAF. Has very
CC       low protein kinase activity and can phosphorylate MAP2K1 at several Ser
CC       and Thr residues with very low efficiency (in vitro). Acts as
CC       MAP2K1/MEK1-dependent allosteric activator of BRAF; upon binding to
CC       MAP2K1/MEK1, dimerizes with BRAF and promotes BRAF-mediated
CC       phosphorylation of MAP2K1/MEK1 (PubMed:29433126). Interaction with BRAF
CC       enhances KSR2-mediated phosphorylation of MAP2K1 (in vitro). Blocks
CC       MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a
CC       negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-
CC       kappa-B pathways, inhibiting MAP3K3-mediated interleukin-8 production.
CC       {ECO:0000269|PubMed:12975377, ECO:0000269|PubMed:16039990,
CC       ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:21441910};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:21441910};
CC   -!- ACTIVITY REGULATION: Kinase activity is inhibited by ASC24.
CC       {ECO:0000269|PubMed:21441910}.
CC   -!- SUBUNIT: Heterodimerizes (via N-terminus) with BRAF (via N-terminus) in
CC       a MAP2K1/MEK1-dependent manner (PubMed:29433126). Interacts with BRAF;
CC       this increases the low intrinsic protein kinase activity of KSR2
CC       (PubMed:21441910). Interacts with MAP2K1, forming a heterodimer that
CC       can dimerize to form a heterotetramer (PubMed:29433126,
CC       PubMed:21441910, PubMed:12975377). Interacts with MAP3K8, MAPK, RAS and
CC       RAF (PubMed:12975377). {ECO:0000269|PubMed:12975377,
CC       ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126}.
CC   -!- INTERACTION:
CC       Q6VAB6; Q16543: CDC37; NbExp=7; IntAct=EBI-6424389, EBI-295634;
CC       Q6VAB6; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-6424389, EBI-3867333;
CC       Q6VAB6; Q13451: FKBP5; NbExp=7; IntAct=EBI-6424389, EBI-306914;
CC       Q6VAB6; P07900: HSP90AA1; NbExp=6; IntAct=EBI-6424389, EBI-296047;
CC       Q6VAB6-1; P29678: MAP2K1; Xeno; NbExp=6; IntAct=EBI-15916808, EBI-1631983;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6VAB6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6VAB6-2; Sequence=VSP_012234, VSP_012235, VSP_012236,
CC                                  VSP_012237;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in brain and kidney.
CC       {ECO:0000269|PubMed:12975377}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive and seems to have very low intrinsic kinase activity. This low
CC       kinase activity can be increased by interaction with BRAF.
CC   -!- PTM: Phosphorylated on Ser-474 by MARK3. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- CAUTION: KSR2 binds ATP and has very low in vitro protein kinase
CC       activity; the physiological relevance of this activity is unknown. KSR2
CC       is proposed to be in an inactive conformation by itself or in complex
CC       with MAP2K1. Interaction with BRAF is proposed to induce a conformation
CC       change that increases the low intrinsic kinase activity
CC       (PubMed:21441910). {ECO:0000305|PubMed:21441910}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK098831; BAC05426.1; -; mRNA.
DR   EMBL; AC073864; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079127; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC084291; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092936; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY345972; AAQ24226.1; -; mRNA.
DR   EMBL; BC107106; AAI07107.1; -; mRNA.
DR   EMBL; BC107107; AAI07108.1; -; mRNA.
DR   EMBL; BC127603; AAI27604.1; -; mRNA.
DR   CCDS; CCDS61250.1; -. [Q6VAB6-1]
DR   RefSeq; NP_775869.3; NM_173598.4. [Q6VAB6-1]
DR   RefSeq; XP_011536527.1; XM_011538225.2.
DR   PDB; 2Y4I; X-ray; 3.46 A; B=634-950.
DR   PDB; 5KKR; X-ray; 3.51 A; B=634-950.
DR   PDB; 7JUQ; X-ray; 3.22 A; B=634-950.
DR   PDB; 7JUR; X-ray; 2.82 A; B=634-950.
DR   PDB; 7JUS; X-ray; 2.99 A; B=634-950.
DR   PDB; 7JUT; X-ray; 3.09 A; B=634-950.
DR   PDB; 7JUU; X-ray; 3.19 A; B=634-950.
DR   PDB; 7JUV; X-ray; 3.36 A; B=634-950.
DR   PDBsum; 2Y4I; -.
DR   PDBsum; 5KKR; -.
DR   PDBsum; 7JUQ; -.
DR   PDBsum; 7JUR; -.
DR   PDBsum; 7JUS; -.
DR   PDBsum; 7JUT; -.
DR   PDBsum; 7JUU; -.
DR   PDBsum; 7JUV; -.
DR   AlphaFoldDB; Q6VAB6; -.
DR   SMR; Q6VAB6; -.
DR   BioGRID; 129567; 19.
DR   DIP; DIP-59195N; -.
DR   IntAct; Q6VAB6; 141.
DR   MINT; Q6VAB6; -.
DR   STRING; 9606.ENSP00000389715; -.
DR   BindingDB; Q6VAB6; -.
DR   ChEMBL; CHEMBL3627583; -.
DR   iPTMnet; Q6VAB6; -.
DR   PhosphoSitePlus; Q6VAB6; -.
DR   BioMuta; KSR2; -.
DR   DMDM; 148886599; -.
DR   jPOST; Q6VAB6; -.
DR   MassIVE; Q6VAB6; -.
DR   MaxQB; Q6VAB6; -.
DR   PaxDb; Q6VAB6; -.
DR   PeptideAtlas; Q6VAB6; -.
DR   PRIDE; Q6VAB6; -.
DR   ProteomicsDB; 67721; -. [Q6VAB6-1]
DR   ProteomicsDB; 67722; -. [Q6VAB6-2]
DR   Antibodypedia; 31354; 363 antibodies from 26 providers.
DR   DNASU; 283455; -.
DR   Ensembl; ENST00000339824.7; ENSP00000339952.4; ENSG00000171435.14. [Q6VAB6-1]
DR   GeneID; 283455; -.
DR   KEGG; hsa:283455; -.
DR   MANE-Select; ENST00000339824.7; ENSP00000339952.4; NM_173598.6; NP_775869.4.
DR   UCSC; uc058tua.1; human. [Q6VAB6-1]
DR   CTD; 283455; -.
DR   DisGeNET; 283455; -.
DR   GeneCards; KSR2; -.
DR   HGNC; HGNC:18610; KSR2.
DR   HPA; ENSG00000171435; Group enriched (brain, pituitary gland).
DR   MIM; 610737; gene.
DR   neXtProt; NX_Q6VAB6; -.
DR   OpenTargets; ENSG00000171435; -.
DR   Orphanet; 521399; NON RARE IN EUROPE: Non rare obesity.
DR   PharmGKB; PA134914125; -.
DR   VEuPathDB; HostDB:ENSG00000171435; -.
DR   eggNOG; KOG0193; Eukaryota.
DR   GeneTree; ENSGT00940000158519; -.
DR   HOGENOM; CLU_006812_1_0_1; -.
DR   InParanoid; Q6VAB6; -.
DR   OMA; QWHWDSW; -.
DR   OrthoDB; 281487at2759; -.
DR   PhylomeDB; Q6VAB6; -.
DR   TreeFam; TF317006; -.
DR   BRENDA; 2.7.11.25; 2681.
DR   PathwayCommons; Q6VAB6; -.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   SignaLink; Q6VAB6; -.
DR   SIGNOR; Q6VAB6; -.
DR   BioGRID-ORCS; 283455; 11 hits in 1086 CRISPR screens.
DR   ChiTaRS; KSR2; human.
DR   GenomeRNAi; 283455; -.
DR   Pharos; Q6VAB6; Tbio.
DR   PRO; PR:Q6VAB6; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; Q6VAB6; protein.
DR   Bgee; ENSG00000171435; Expressed in Brodmann (1909) area 23 and 82 other tissues.
DR   ExpressionAtlas; Q6VAB6; baseline and differential.
DR   Genevisible; Q6VAB6; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0007265; P:Ras protein signal transduction; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   CDD; cd00029; C1; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR025561; KSR_SAM-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF13543; SAM_KSR1; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..950
FT                   /note="Kinase suppressor of Ras 2"
FT                   /id="PRO_0000086231"
FT   DOMAIN          666..931
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         412..456
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          239..296
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          498..556
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        280..294
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        512..527
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        528..549
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        786
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000305|PubMed:21441910"
FT   BINDING         413
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         425
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         428
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         438
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         441
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         446
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         449
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250"
FT   BINDING         456
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250"
FT   BINDING         672..680
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:21441910"
FT   BINDING         788
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:21441910"
FT   BINDING         803
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305|PubMed:21441910"
FT   MOD_RES         272
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVC0"
FT   MOD_RES         276
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVC0"
FT   MOD_RES         474
FT                   /note="Phosphoserine; by MARK3"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         497
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVC0"
FT   VAR_SEQ         1..303
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012234"
FT   VAR_SEQ         304..329
FT                   /note="GFTALHRSKSHEFQLGHRVDEAHTPK -> MYNKKAKMEPNASESAIPARRQ
FT                   RQPR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012235"
FT   VAR_SEQ         740..742
FT                   /note="SLC -> RPV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012236"
FT   VAR_SEQ         743..950
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_012237"
FT   VARIANT         676
FT                   /note="R -> S (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040659"
FT   MUTAGEN         718
FT                   /note="R->H: Impairs formation of heterotetramers with
FT                   MAP2K1, but not the formation of heterodimers."
FT                   /evidence="ECO:0000269|PubMed:21441910"
FT   MUTAGEN         786
FT                   /note="D->A: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:21441910"
FT   MUTAGEN         879
FT                   /note="A->L: Impairs MAP2K1 binding."
FT                   /evidence="ECO:0000269|PubMed:21441910"
FT   HELIX           656..658
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          659..661
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          667..673
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          676..684
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          688..695
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          698..700
FT                   /evidence="ECO:0007829|PDB:7JUQ"
FT   HELIX           701..714
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          725..727
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          734..740
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          744..746
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           747..751
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           760..779
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           789..791
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          792..795
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          798..801
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           806..809
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   STRAND          821..825
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   TURN            826..828
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           829..831
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           834..837
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           846..848
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           853..869
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   TURN            873..876
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           879..887
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           895..897
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           901..910
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           915..917
FT                   /evidence="ECO:0007829|PDB:7JUR"
FT   HELIX           921..929
FT                   /evidence="ECO:0007829|PDB:7JUR"
SQ   SEQUENCE   950 AA;  107632 MW;  DFBC20F4E71077AD CRC64;
     MDEENMTKSE EQQPLSLQKA LQQCELVQNM IDLSISNLEG LRTKCATSND LTQKEIRTLE
     SKLVKYFSRQ LSCKKKVALQ ERNAELDGFP QLRHWFRIVD VRKEVLEEIS PGQLSLEDLL
     EMTDEQVCET VEKYGANREE CARLNASLSC LRNVHMSGGN LSKQDWTIQW PTTETGKENN
     PVCPPEPTPW IRTHLSQSPR VPSKCVQHYC HTSPTPGAPV YTHVDRLTVD AYPGLCPPPP
     LESGHRSLPP SPRQRHAVRT PPRTPNIVTT VTPPGTPPMR KKNKLKPPGT PPPSSRKLIH
     LIPGFTALHR SKSHEFQLGH RVDEAHTPKA KKKSKPLNLK IHSSVGSCEN IPSQQRSPLL
     SERSLRSFFV GHAPFLPSTP PVHTEANFSA NTLSVPRWSP QIPRRDLGNS IKHRFSTKYW
     MSQTCTVCGK GMLFGLKCKN CKLKCHNKCT KEAPPCHLLI IHRGDPARLV RTESVPCDIN
     NPLRKPPRYS DLHISQTLPK TNKINKDHIP VPYQPDSSSN PSSTTSSTPS SPAPPLPPSA
     TPPSPLHPSP QCTRQQKNFN LPASHYYKYK QQFIFPDVVP VPETPTRAPQ VILHPVTSNP
     ILEGNPLLQI EVEPTSENEE VHDEAEESED DFEEMNLSLL SARSFPRKAS QTSIFLQEWD
     IPFEQLEIGE LIGKGRFGQV YHGRWHGEVA IRLIDIERDN EDQLKAFKRE VMAYRQTRHE
     NVVLFMGACM SPPHLAIITS LCKGRTLYSV VRDAKIVLDV NKTRQIAQEI VKGMGYLHAK
     GILHKDLKSK NVFYDNGKVV ITDFGLFSIS GVLQAGRRED KLRIQNGWLC HLAPEIIRQL
     SPDTEEDKLP FSKHSDVFAL GTIWYELHAR EWPFKTQPAE AIIWQMGTGM KPNLSQIGMG
     KEISDILLFC WAFEQEERPT FTKLMDMLEK LPKRNRRLSH PGHFWKSAEL
//
